Navigation Links
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:4/26/2008

rm vs. Pegasys arm].

-- Safety and tolerability were similar among the three treatment groups, with no new peginterferon or ribavirin related adverse events identified in this large study. Overall adverse events reported for the three treatment regimens were similar. As seen in other studies with these treatments, a range of "flu-like symptoms" were the most commonly reported adverse events for all three treatment regimens. Overall, the proportion of patients reporting serious adverse events was similar (9 vs. 9 vs. 12 percent, respectively). Discontinuation rates due to adverse events were similar across the three treatment arms (13 vs. 10 vs. 13 percent, respectively) as were discontinuations due to psychiatric adverse events (3 vs. 2 vs. 2 percent, respectively).

The complete results of the IDEAL study will be submitted for peer-reviewed publication, as well as to health authorities worldwide.

About IDEAL

The IDEAL study was undertaken by Schering-Plough as an important step in meeting the needs of the hepatitis C medical and patient communities to identify improved treatment strategies to optimize outcomes for patients. IDEAL, a Phase IIIb, randomized, parallel-group study, was conducted at 118 academic and community centers across the United States. The study treated 3,070 adult patients with chronic HCV genotype 1. Of these, 82 percent of patients had high viral load (greater than 600,000 IU/mL),(3) 11 percent had grade F3/4 fibrosis/cirrhosis, and 19 percent were African Americans. There were no significant differences in patient demographics or disease characteristics across the three treatment arms.

The comparison of the two PEGINTRON combination therapy doses (1.5 vs. 1.0 mcg/kg/week) was conducted as a post-approval commitment to the U.S. Food and Drug Administration (FDA). The comparison of the PEGINTRON and Pegasys combination therapy regimens was added to the study because no randomized, controlled head-to-head study
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
3. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
4. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
11. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)... Nov. 26, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has issued a ... (NDA) for AVP-825. AVP-825 is an investigational drug-device ... intranasally utilizing a novel Breath Powered delivery technology. ... and consistent with the preliminary feedback announced on ...
(Date:11/26/2014)... Investor-Edge has initiated coverage on the following equities: VIVUS ... HZNP ), Endocyte Inc. (NASDAQ: ECYT ... Theravance Inc. (NASDAQ: THRX ). Free research on ... . On Tuesday, November 25, 2014, the NASDAQ Composite ... edged 0.02% lower, to finish the day at 17,814.94, and ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
(Date:11/28/2014)... 2014 UniWigs.com, a leader in the wig industry, ... to the next Monday. This promotion features: , ... items up to 70% off (no coupon code needed), ... Free shipping on orders over $49 , Visit http://www.uniwigs.com ... from Nov. 28th to Dec. 1st and the first 100 shoppers ...
(Date:11/28/2014)... November 28, 2014 An inventor from Flint, ... to day. "I got this idea while lying in a ... bathroom," he said. , The Bed Buddy provides a more ... to the bathroom. It eliminates the need to leave the ... comfort and dignity. Easy to use and producible in design ...
(Date:11/28/2014)... 28, 2014 talklocal ( http://www.talklocal.com ... the right service professionals by phone in about 90 seconds. ... least two tornadoes were reported to have touched down just ... was reported following the tornadoes, Denver residents now know all ... Having TalkLocal is like having local pros in over 50 ...
(Date:11/28/2014)... November 28, 2014 This report ... market along with the definite portrayal of the ... point depiction of various variables driving the development ... difficulties blocking the development of the business. ... , According to the report "Worldwide Dental ...
(Date:11/27/2014)... (PRWEB) November 28, 2014 One ... implant dentistry. The market for implant dentistry comprises ... tools/instruments. The global market for dental care is ... equipments. The dental equipment segment is composed of ... of contents at: http://www.researchmoz.us/global-dental-market-report-2014-edition-report.html , The ...
Breaking Medicine News(10 mins):Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2Health News:TalkLocal Launches In Denver A Week After Multiple Tornadoes Hit Near City 2Health News:Global Dental Market Report 2014 Edition Now Available at MarketReportsOnline.com 2Health News:Global Dental Market Report 2014 Edition Now Available at MarketReportsOnline.com 3Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 3
... to be more effective than placebos in treating rapid ... study , which included 38 non-schizophrenic, non-bipolar women with ... 51 was conducted by researchers from various universities in ... shift, impulsivity and aggression when given fluvoxamine or a ...
... a national survey of more than 149,000 Americans including 23,000 ... 25% of adults with disabilities, compared to 16 per cent ... defined as having a Body Mass Index greater than 32. ... mobility difficulties and those who had not received exercise counselling ...
... on both mice and humans are showing why some people absorb ... if you eat a fatty meal or snack - a fried ... you absorb is strongly influenced by your genes. Experts know that ... fat diet is bad for you. But little has been discovered ...
... in there study are trying to observe why surgery ... ongoing. It's long been known that some older people develop ... - a condition known as Post Operative Cognitive Dysfunction (POCD).Often ... same' as they were before surgery. It was assumed, at ...
... observed that a drug already being used to treat ... male contraceptive. Researchers hypothesized N-butyldeoxynojirimycin, or NB-DNJ, which has ... work// as a male contraceptive because it affects the ... tested their theory in an animal study involving mice. ...
... the eye has prevented and stopped autoimmune eye disease in ... treatments for other// autoimmune diseases such as multiple sclerosis and ... Institute in Boston found the factor alpha-MSH can be harnessed ... prevent the onset of and stop the progression of uveitis ...
Cached Medicine News:
Provides secure fracture immobilization while allowing for full range of motion at elbow and wrist...
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
... 3-Point® Polycentric Hinged Ulnar Deviation Splint ... align the hand with ulnar deviation at ... impede grasp or pinch. Radial and ulnar ... ensure unimpeded flexion and extension. Padded, malleable ...
... Boxer Fracture Prefab Orthosis For quick, ... Rigid Kydex shell immobilizes and protects ... padded interior adds comfort, support, and ... hard-to-fit cases, the shell may be ...
Medicine Products: